keyword
MENU ▼
Read by QxMD icon Read
search

Long acting antipsychotics

keyword
https://www.readbyqxmd.com/read/29440904/discrepancy-in-taiwanese-psychiatrists-preferences-for-long-acting-injectable-antipsychotics-across-facilities-a-nationwide-questionnaire-survey
#1
Chun-Hao Liu, Po-Hsin Tsai, Ching-Yen Chen
Background: Although many studies have discussed psychiatrists' attitudes toward long-acting injectable antipsychotics (LAIs), no previous study has focused on differences in preference based on the facilities in which the psychiatrists practiced. Materials and methods: A pilot survey was conducted in a medical center in northern Taiwan, and a questionnaire was then distributed at the annual conference of the Taiwanese Society of Psychiatry in 2013. The questionnaire included general demographic data and preferences for the use of LAIs in different situations...
2018: Neuropsychiatric Disease and Treatment
https://www.readbyqxmd.com/read/29402652/fall-risk-increasing-drugs-a-systematic-review-and-meta-analysis-ii-psychotropics
#2
Lotta J Seppala, Anne M A T Wermelink, Max de Vries, Kimberley J Ploegmakers, Esther M M van de Glind, Joost G Daams, Nathalie van der Velde
BACKGROUND AND OBJECTIVE: Falls are a major public health problem in older adults. Earlier studies showed that psychotropic medication use increases the risk of falls. The aim of this study is to update the current knowledge by providing a comprehensive systematic review and meta-analysis on psychotropic medication use and falls in older adults. METHODS AND DESIGN: This study is a systematic review and meta-analysis. A search was conducted in Medline, PsycINFO, and Embase...
February 2, 2018: Journal of the American Medical Directors Association
https://www.readbyqxmd.com/read/29395607/a-quantitative-systems-pharmacology-study-on-optimal-scenarios-for-switching-to-paliperidone-palmitate-once-monthly
#3
Hugo Geerts, Athan Spiros, Patrick Roberts, Larry Alphs
Long-acting injectable (LAI) antipsychotic formulations are increasingly used for improving patient compliance and long-term outcomes. Transitioning to LAIs raises questions regarding how optimum efficacy can be rapidly achieved while minimizing potential efficacy and safety concerns related to overlapping plasma levels of prior treatments and the new LAI. Ideally, randomized clinical trials would provide guidance regarding transition algorithms, but the number of studies and sample size required to address relevant questions makes this approach unachievable...
January 25, 2018: Schizophrenia Research
https://www.readbyqxmd.com/read/29381388/long-acting-injectable-atypical-antipsychotic-use-in-adolescents-an-observational-study
#4
Adriana Fortea, Daniel Ilzarbe, Laura Espinosa, Mireia Solerdelcoll, Clara de Castro, Giovanni Oriolo, Gisela Sugranyes, Inmaculada Baeza
OBJECTIVES: Although second generation long-acting injectable antipsychotics (SG-LAIAs) have been approved and are widely used in adults, there is limited evidence for the use of long-acting formulations in children and adolescents. Thus, we systematically describe the off-label use of SG-LAIAs in clinical practice in adolescent inpatients. METHODS: All individuals admitted to our Children and Adolescent Inpatient Psychiatry Unit receiving treatment with SG-LAIAs between January 2013 and June 2016 were reviewed...
January 30, 2018: Journal of Child and Adolescent Psychopharmacology
https://www.readbyqxmd.com/read/29379293/efficacy-and-safety-profile-of-paliperidone-palmitate-injections-in-the-management-of-patients-with-schizophrenia-an-evidence-based-review
#5
REVIEW
Robin Emsley, Sanja Kilian
The course of schizophrenia is characterized by multiple relapses, incomplete remission of symptoms, enduring cognitive deficits, and social and occupational functional impairments. Nonadherence to antipsychotic medication is a major determinant of this poor outcome. Long-acting injectable antipsychotics were developed specifically to address the nonadherence problem and are increasingly considered as an early treatment option, in an attempt to prevent accruing morbidity. This review focuses on paliperidone palmitate, the long-acting injectable (LAI) formulation of paliperidone...
2018: Neuropsychiatric Disease and Treatment
https://www.readbyqxmd.com/read/29378547/the-research-and-evaluation-of-antipsychotic-treatment-in-community-behavioral-health-organizations-outcomes-reach-out-study-real-world-clinical-practice-in-schizophrenia
#6
Kruti Joshi, Lian Mao, David M Biondi, Robert Millet
BACKGROUND: Outpatient facilities, such as community behavioral health organizations (CBHOs), play a critical role in the care of patients with serious mental illness, but there is a paucity of "real-world" patient outcomes data from this health care setting. Therefore, we conducted The Research and Evaluation of Antipsychotic Treatment in Community Behavioral Health Organizations, Outcomes (REACH-OUT) trial, a real-world, prospective, noninterventional observational study of patients with mental illness treated at CBHOs across the United States...
January 29, 2018: BMC Psychiatry
https://www.readbyqxmd.com/read/29350127/converting-oral-to-long-acting-injectable-antipsychotics-a-guide-for-the-perplexed
#7
Jonathan M Meyer
There has been increasing recognition that antipsychotic nonadherence is common across all stages of schizophrenia, starting from the first episode. Moreover, numerous meta-analyses of the existing literature indicate superiority of long-acting injectable (LAI) over oral antipsychotics when one adjusts for the greater illness severity and duration among patients in LAI antipsychotic trials. The increasing availability of LAI antipsychotic options has raised interest in converting patients from oral medication; however, the successful transition from oral to the comparable LAI antipsychotic requires an understanding of the current extent of antipsychotic exposure, the kinetics of the LAI preparation, and the expected plasma levels achieved by the LAI formulation...
December 2017: CNS Spectrums
https://www.readbyqxmd.com/read/29345879/improving-long-term-outcomes-in-patients-with-schizophrenia-what-is-the-evidence-for-long-acting-injectable-antipsychotics
#8
Diana O Perkins
Do you consider long-acting injectable (LAI) antipsychotics when selecting among treatments for schizophrenia? Take part in this CME activity to review the evidence for LAIs vs oral medications and to learn which patients may benefit most from this treatment option. Plus, discover the pharmacokinetic properties of LAIs and barriers to their use.
November 2017: Journal of Clinical Psychiatry
https://www.readbyqxmd.com/read/29343694/sertraline-paroxetine-and-chlorpromazine-are-rapidly-acting-anthelmintic-drugs-capable-of-clinical-repurposing
#9
Janis C Weeks, William M Roberts, Caitlyn Leasure, Brian M Suzuki, Kristin J Robinson, Heather Currey, Phurpa Wangchuk, Ramon M Eichenberger, Aleen D Saxton, Thomas D Bird, Brian C Kraemer, Alex Loukas, John M Hawdon, Conor R Caffrey, Nicole F Liachko
Parasitic helminths infect over 1 billion people worldwide, while current treatments rely on a limited arsenal of drugs. To expedite drug discovery, we screened a small-molecule library of compounds with histories of use in human clinical trials for anthelmintic activity against the soil nematode Caenorhabditis elegans. From this screen, we found that the neuromodulatory drugs sertraline, paroxetine, and chlorpromazine kill C. elegans at multiple life stages including embryos, developing larvae and gravid adults...
January 17, 2018: Scientific Reports
https://www.readbyqxmd.com/read/29284436/health-care-use-drug-treatment-and-comorbidity-in-patients-with-schizophrenia-or-non-affective-psychosis-in-sweden-a-cross-sectional-study
#10
Erica M Brostedt, Mussie Msghina, Marie Persson, Björn Wettermark
BACKGROUND: This study investigated the prevalence of schizophrenia (ICD-10 F 20) and of other non-affective psychosis (NAP, ICD-10 F 21 - F 29) in Sweden. It further assessed health care use, comorbidity and medication for these patient groups. Most studies either have a study population of patients with strictly defined schizophrenia or a psychosis population of which strict schizophrenia cases form a smaller set. The present study permits comparison of the two mutually exclusive patient groups using data at the individual level in the diagnosis of non-affective psychosis, use of health care, medical treatment and comorbidity by diagnosis or medical treatment...
December 29, 2017: BMC Psychiatry
https://www.readbyqxmd.com/read/29274734/antipsychotics-and-mortality-in-a-nationwide-cohort-of-29-823-patients-with-schizophrenia
#11
Heidi Taipale, Ellenor Mittendorfer-Rutz, Kristina Alexanderson, Maila Majak, Juha Mehtälä, Fabian Hoti, Erik Jedenius, Dana Enkusson, Amy Leval, Jan Sermon, Antti Tanskanen, Jari Tiihonen
INTRODUCTION: It has remained controversial if antipsychotic treatment is associated with increased or decreased mortality among patients with schizophrenia, and if there are any clinically meaningful differences between specific agents and routes of administration. METHODS: We linked prospectively gathered nationwide register-based data during 2006-2013 to study all-cause mortality among all patients aged 16-64years with schizophrenia in Sweden (N=29,823 in total; N=4603 in the incident cohort)...
December 20, 2017: Schizophrenia Research
https://www.readbyqxmd.com/read/29238631/ethnic-and-age-disparities-in-patients-taking-long-acting-injectable-atypical-antipsychotics
#12
Mateen Soleman, Nikki Lam, Benjamin K Woo
Introduction This study will determine whether different ethnicities and different age groups receive equal amounts of long-acting atypical antipsychotics in comparison to their oral equivalents. Methods Secondary analyses of data from the Los Angeles County Department of Health Services Electronic Health Record (total N=63,134 inpatient visits) were performed. Chi-squared statistics were used to compare ethnicity and age with the use of either risperidone injectable or paliperidone palmitate (r-LAIs) versus risperidone oral...
October 12, 2017: Curēus
https://www.readbyqxmd.com/read/29232310/comparison-of-paliperidone-palmitate-and-risperidone-long-acting-injection-in-schizophrenic-patients-results-from-a-multicenter-retrospective-cohort-study-in-france
#13
Frédéric Limosin, Drifa Belhadi, Denis Comet, Maud Pacou, Sophie Bouju, Kristel Van Impe, Pascal Guillon
PURPOSE/BACKGROUND: The study objective was to compare the impact of being treated by paliperidone palmitate (PP) or risperidone long-acting injection (RLAI) on the length of stay on initial hospitalization, rehospitalization risk, and treatment duration in schizophrenic patients. METHODS: We conducted an observational retrospective cohort study in 43 centers in France, including schizophrenic patients who initiated a treatment by PP or RLAI during initial hospitalization...
February 2018: Journal of Clinical Psychopharmacology
https://www.readbyqxmd.com/read/29187753/subchronic-olanzapine-exposure-leads-to-increased-expression-of-myelination-related-genes-in-rat-fronto-medial-cortex
#14
Kari M Ersland, Silje Skrede, Christine Stansberg, Vidar M Steen
Schizophrenia is a psychotic disorder with severe and disabling symptoms, such as hallucinations, delusions, blunted affect and social withdrawal. The neuropathology remains elusive, but disturbances in immunity-related processes, neuronal connectivity and myelination have consistently been linked to schizophrenia. Antipsychotic drugs can be efficient in reducing symptoms, acting primarily on the dopamine system, but additional biological targets are likely to exist. Here we have screened for novel mechanisms of action in an animal model, using adult rats exposed to long-acting olanzapine, achieving stable and clinically relevant antipsychotic drug concentrations...
November 30, 2017: Translational Psychiatry
https://www.readbyqxmd.com/read/29185542/pimavanserin-a-novel-therapeutic-option-for-parkinson-disease-psychosis
#15
REVIEW
Trevor Hawkins, Brian D Berman
Purpose of review: In April 2016, the Food and Drug Administration (FDA) approved a first-in-class atypical antipsychotic medication called pimavanserin for the treatment of Parkinson disease psychosis (PDP). We aim to inform readers about its indications, effectiveness, and safety profile. Recent findings: Pimavanserin acts as an inverse agonist at serotonin 5-HT2A receptors and has negligible effects on other receptors, thereby avoiding the D2 receptor antagonism that can potentially worsen motor symptoms...
April 2017: Neurology. Clinical Practice
https://www.readbyqxmd.com/read/29179595/efficacy-and-safety-of-aripiprazole-lauroxil-once-monthly-versus-aripiprazole-once-monthly-long-acting-injectable-formulations-in-patients-with-acute-symptoms-of-schizophrenia-an-indirect-comparison-of-two-double-blind-placebo-controlled-studies
#16
Chris Cameron, Jacqueline Zummo, Dharmik Desai, Christine Drake, Brian Hutton, Ahmed Kotb, Peter J Weiden
BACKGROUND: Aripiprazole lauroxil (AL) is a long-acting injectable atypical antipsychotic recently approved for the treatment of schizophrenia. OBJECTIVE: To indirectly compare the safety and efficacy of AL and aripiprazole once-monthly (AOM). METHODS: We performed a systematic search to identify randomized, controlled trials of AOM and AL that met criteria for indirect comparison according to Bayesian network meta-analysis. The analysis indirectly compared AL and AOM treatment groups for efficacy by mean change in Positive and Negative Syndrome Scale (PANSS) total score and ≥30% reduction in PANSS total score, as well as tolerability including adverse events, akathisia, and weight gain...
November 27, 2017: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/29179228/can-we-rely-on-agnp-therapeutic-targets-also-for-lai-antipsychotics
#17
Sara Baldelli, Emilio Clementi, Dario Cattaneo
The updated AGNP Consensus Guidelines for Therapeutic Drug Monitoring (TDM) in Neuropsychopharmacology recently published in the journal have reinforced the key role of TDM to individualize psychoparmacological therapies in clinical practice. However, we believe, that these guidelines have missed the important opportunity to face with, and to provide useful information on, the emerging issue of long-acting injectable formulations of atypical antipsychotics. Specific therapeutic ranges also for these formulations should be included in the next AGNP guidelines...
November 27, 2017: Pharmacopsychiatry
https://www.readbyqxmd.com/read/29177572/aripiprazole-lauroxil-a-review-in-schizophrenia
#18
James E Frampton
Aripiprazole lauroxil long-acting injectable (LAI) [Aristada®] is an intramuscularly administered, extended-release prodrug of aripiprazole, an established atypical antipsychotic agent that, in terms of its relative position within the class, is at the low end of the risk spectrum for metabolic side effects. In the USA, aripiprazole lauroxil LAI is indicated for the treatment of schizophrenia; approved doses of the drug can be injected once-monthly (q4w), every 6 weeks (q6w) or every 2 months (q8w). The efficacy of the 441 and 882 mg q4w dosages in the treatment of acute exacerbations of schizophrenia and as long-term maintenance therapy in stable schizophrenia has been directly demonstrated in a phase III clinical trial and extension, while the efficacy of the 662 mg q4w, 882 mg q6w and 1064 mg q8w dosing regimens has been established on the basis of pharmacokinetic bridging studies...
November 25, 2017: Drugs
https://www.readbyqxmd.com/read/29174738/symptoms-and-functioning-with-aripiprazole-once-monthly-injection-as-maintenance-treatment-for-bipolar-i-disorder
#19
Joseph R Calabrese, Raymond Sanchez, Na Jin, Joan Amatniek, Kevin Cox, Brian Johnson, Pamela Perry, Peter Hertel, Pedro Such, Robert D McQuade, Margaretta Nyilas, William H Carson
BACKGROUND: Effects of maintenance treatment with aripiprazole once-monthly 400mg (AOM 400) on symptoms and functioning were assessed in adults with bipolar I disorder (BP-I) after a manic episode. METHODS: Patients were stabilized on oral aripiprazole, cross-titrated to AOM 400, then randomized in a 52-week, double-blind, placebo-controlled, withdrawal phase. Prespecified secondary outcomes are reported: time to hospitalization for mood episode, Young Mania Rating Scale (YMRS), Montgomery-Åsberg Depression Rating Scale (MADRS), Clinical Global Impression-Bipolar scale, Functioning Assessment Short Test (FAST), and Brief Quality of Life in Bipolar Disorder questionnaire...
October 24, 2017: Journal of Affective Disorders
https://www.readbyqxmd.com/read/29168261/-impact-of-drug-reimbursement-policies-on-prescribing-a-case-study-of-a-newly-marketed-long-acting-injectable-antipsychotics-among-relapsed-schizophrenia-patients
#20
John W Jackson, Lisa Fulchino, James Rogers, Helen Mogun, Jennifer Polinski, David C Henderson, Sebastian Schneeweiss, Michael A Fischer
OBJECTIVE: To quantify and explain variation in use of long-acting injectable antipsychotics (LAIs) in the United States, and understand the relationship between patient characteristics, drug reimbursement policies, and LAI prescribing after relapse. METHODS: A cohort of recently relapsed patients with schizophrenia ages 18 to 64, identified immediately after discharge from a related inpatient hospitalization, partial hospitalization, or emergency room visit, drawn from 2004 to 2006 Medicaid claims, and followed for 90 days until LAI initiation...
November 23, 2017: Pharmacoepidemiology and Drug Safety
keyword
keyword
81198
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"